RedHawk (SNDD) 10-Q 19 Feb 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Dec. 31, 2019	Feb. 11, 2020
Cover [Abstract]
Entity Registrant Name	RedHawk Holdings Corp.
Entity Central Index Key	0001353406
Document Type	10-Q
Document Period End Date	Dec. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Entity Incorporation, State or Country Code	NV
Entity File Number	000-54323
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		969,159,469
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020

Consolidated Balance Sheets (un

Consolidated Balance Sheets (unaudited) - USD ($)	Dec. 31, 2019	Jun. 30, 2019
Current Assets:
Cash	$ 176,145	$ 1,648
Certificate of deposit	100,374	100,374
Receivables	12,130
Inventory, at cost	220,198	181,227
Prepaid expenses	299,922	122,436
Total Current Assets	808,769	405,685
Property and Improvements:
Land	110,000	110,000
Building and improvements	670,000	670,000
Property and Improvements Before Depreciation	780,000	780,000
Less, accumulated depreciation	(128,146)	(112,479)
Total Property and Improvement	651,854	667,521
Other Assets:
Investment in real estate limited partnership	257,173	257,173
Intangible asset, net of amortization of $431,196 and $404,946, respectively	816,094	848,992
Other assets	131,752	129,962
Total Other Assets	1,205,019	1,236,127
Total Assets	2,665,642	2,309,333
Current Liabilities:
Accounts payable and accrued liabilities	889,344	899,685
Current maturities of long-term debt	188,485	184,585
Lines of credit	203,307	253,219
Insurance notes payable	159,799	136,859
Total Current Liabilities	1,440,935	1,474,348
Non-current Liabilities
Due to related parties	242,000	230,250
Other non-current liabilities	723,750	703,750
Real estate note payable, net of current maturities	219,057	224,097
Convertible notes payable, net of $110,882 and $49,241 in deferred loan costs	1,289,544	342,304
Total Long-Term Debt	2,474,351	1,500,401
Total Liabilities	3,915,286	2,974,749
Commitments and Contingencies
Stockholders' Equity (Deficit):
Preferred stock, value
Common Stock, par value of $0.001 per share, 2,000,000,000 authorized shares and 1,170,708,112 and 1,034,340,037 issued, respectively	1,170,708	1,034,340
Additional paid-in capital	443,240	51,811
Accumulated other comprehensive loss	(1,494)	2,735
Accumulated deficit	(6,559,880)	(5,674,436)
Total Stockholders' Equity (Deficit) Before Treasury Stock	(669,286)	(85,058)
Less, Treasury stock 201,548,643 shares, at cost	(580,358)	(580,358)
Total Stockholders' Equity (Deficit)	(1,249,644)	(665,416)
Total Liabilities and Stockholders' Equity (Deficit)	2,665,642	2,309,333
5% Series A Preferred Stock [Member]
Stockholders' Equity (Deficit):
Preferred stock, value	3,065,337	3,021,453
5% Series B Preferred Stock [Member]
Stockholders' Equity (Deficit):
Preferred stock, value	$ 1,212,803	$ 1,479,039

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (unaudited) (Parenthetical) - USD ($)	Dec. 31, 2019	Jun. 30, 2019
Amortization of intangible assets	$ 431,196	$ 404,946
Deferred loan costs, noncurrent	$ 110,882	$ 49,241
Preferred stock, authorized	5,000	5,000
Preferred stock, issued	3,750	4,000
Preferred stock, outstanding	3,750	4,000
Common Stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, authorized	2,000,000,000	2,000,000,000
Common Stock, issued	1,170,708,112	1,034,340,037
Treasury stock	201,548,643	201,548,643
5% Series A Preferred Stock [Member]
Preferred stock, value (in dollars per share)	$ 1,115	$ 1,099
Preferred stock, designated	2,750	2,750
Preferred stock, issued	2,750	2,750
Preferred stock, outstanding	2,750	2,750
5% Series B Preferred Stock [Member]
Preferred stock, value (in dollars per share)	$ 1,213	$ 1,183
Preferred stock, designated	1,250	1,250
Preferred stock, issued	1,000	1,250
Preferred stock, outstanding	1,000	1,250

Consolidated Statements of Oper

Consolidated Statements of Operations (unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Revenues	$ 18,757	$ 48,852	$ 69,315	$ 95,520
Operating Expenses:
Costs of goods sold	7,068	4,064	16,921	31,030
Sales and marketing expenses	66,680	13,359	117,871	24,895
Professional fees	97,141	133,751	167,360	166,767
Research and development costs	34,639		58,481
Operating expenses	99,183	19,362	136,097	39,411
Depreciation and amortization	20,959	30,402	41,917	61,151
General and administrative	102,267	60,728	134,533	93,094
Total Operating Expenses	427,937	261,666	673,180	416,348
Net Loss from Operations	(409,180)	(212,814)	(603,865)	(320,828)
Other Income (Expense):
Gain on early extinguishment of debt			44,527
Settlement loss		(396,500)		(396,500)
Interest expense	(123,643)	(92,615)	(211,515)	(181,218)
Total Other Income (Expense)	(123,643)	(489,115)	(166,988)	(577,718)
Net Loss	(532,823)	(701,929)	(770,853)	(898,546)
Other comprehensive income:
Effect of foreign currency translation	(1,442)	(52)	(4,229)	2,787
Total Other comprehensive income	(1,442)	(52)	(4,229)	2,787
Comprehensive Loss	(534,265)	(701,981)	(775,082)	(895,759)
Preferred Stock Dividends	(53,014)	(38,820)	(114,591)	(77,160)
Comprehensive Loss Available for Common Stockholders	$ (587,279)	$ (740,801)	$ (889,673)	$ (972,919)
Net Loss Per Share
Basic (in dollars per share)
Diluted (in dollars per share)
Weighted Average Shares Outstanding
Basic (in shares)	928,445,010	495,163,432	903,080,360	421,615,585
Diluted (in shares)	928,445,010	495,163,432	903,080,360	421,615,585

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (unaudited) - USD ($)	6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (770,853)	$ (898,546)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of intangibles	26,250	45,485
Amortization of discount on convertible debentures		10,900
Amortization of deferred loan costs	50,705	40,631
Depreciation	15,667	15,666
Non-cash interest expenses	202,308	58,873
Non-cash settlement loss		396,500
Gain on extinguishment of debt	(44,527)
Changes in operating assets and liabilities:
Accounts receivable	(12,130)	5,259
Inventory	(34,201)	19,073
Prepaid expense and other assets	(142,446)	1,834
Accounts payable and accrued liabilities	(123,643)	(81)
Net Cash Used in Operating Activities	(832,870)	(304,406)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from distribution from limited liability partnership		367,827
Purchase of license		(25,000)
Net Cash Provided by Investing Activities		342,827
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from (payments to) related parties, net	11,750	(12,674)
Proceeds from issuance of convertible debt	1,340,125	143,000
Payments on convertible debt	(215,250)	(132,727)
Costs related to debt for equity conversions		(10,300)
Deferred loan costs	(111,022)	(18,500)
Proceeds from lines of credit	16,470
Payments on lines of credit	(62,482)
Net proceeds from (payments on) insurance notes payable	22,940	(4,157)
Principal payments on long-term debt	(5,040)	(4,472)
Net Cash Provided by (Used in) Financing Activities	997,491	(39,830)
Effect of exchange rate on cash	9,876	(2,857)
Net change in cash	174,497	(4,266)
Cash, Beginning of Period	1,648	19,034
Cash, End of Period	176,145	14,768
Non-Cash Investing and Financing Activities:
Preferred stock dividends paid-in-kind	77,345	77,160
Conversion of debt to common stock	117,318	166,489
Common stock issued in lieu of cash for services and assets	97,810	17,500
Conversion of preferred stock to common stock	299,696
Increase in liabilities related to license agreement acquisition		425,000
Supplemental Disclosures:
Interest paid	80,158	22,650
Income taxes paid

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) (unaudited) - USD ($)	SERIES A PREFERRED STOCK [Member]	SERIES B PREFERRED STOCK [Member]	COMMON STOCK [Member]	ADDITIONAL PAID-IN CAPITAL [Member]	ACCUMULATED OTHER COMPREHENSIVE LOSS [Member]	ACCUMULATED DEFICIT [Member]	TREASURY STOCK [Member]	NONCONTROLLING INTEREST [Member]	Total
Balance at beginning at Jun. 30, 2018	$ 1,659,889	$ 1,407,342	$ 398,411	$ 1,311,076		$ (4,302,291)	$ (365,352)		$ 109,075
Balance at beginning (in shares) at Jun. 30, 2018	1,473	1,250	398,410,762				35,471,535
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Preferred stock dividends declared	$ 41,757	$ 35,403				(77,160)
Conversions			$ 132,655	23,535					156,190
Conversions (in shares)			132,654,640
Stock grants			$ 29,400	7,350					36,750
Stock grants (in shares)			29,400,000
Net loss					2,787	(898,546)			(895,759)
Balance at ending at Dec. 31, 2018	$ 1,701,646	$ 1,442,745	$ 560,466	$ 1,341,961	$ 2,787	$ (5,277,997)	$ (365,352)		(593,744)
Balance at ending (in shares) at Dec. 31, 2018	1,473	1,250	560,465,402				35,471,535
Balance at beginning at Sep. 30, 2018	$ 1,680,638	$ 1,424,933	$ 514,066	$ 1,330,361	$ 2,839	$ (4,537,248)	$ (365,352)		50,237
Balance at beginning (in shares) at Sep. 30, 2018	1,473	1,250	514,065,402				35,471,535
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Preferred stock dividends declared	$ 21,008	$ 17,812				(38,820)
Conversions			$ 17,000	4,250					21,250
Conversions (in shares)			17,000,000
Stock grants			$ 29,400	7,350					36,750
Stock grants (in shares)			29,400,000
Net loss			$ 52			(701,929)			(701,981)
Balance at ending at Dec. 31, 2018	$ 1,701,646	$ 1,442,745	$ 560,466	$ 1,341,961	$ 2,787	$ (5,277,997)	$ (365,352)		(593,744)
Balance at ending (in shares) at Dec. 31, 2018	1,473	1,250	560,465,402				35,471,535
Balance at beginning at Jun. 30, 2019	$ 3,021,453	$ 1,479,039	$ 1,034,340	$ 51,811	$ 2,735	$ (5,674,436)	$ (580,358)		(665,416)
Balance at beginning (in shares) at Jun. 30, 2019	2,750	1,250	1,034,340,037				201,548,643
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Preferred stock dividends declared	$ 43,884	$ 33,460				(114,591)			(37,247)
Conversions		$ (299,696)	$ 86,433	286,054					72,791
Conversions (in shares)		(250)	86,433,293
Stock grants			$ 49,935	105,375					155,310
Stock grants (in shares)			49,934,782
Shares acquired
Net loss					(4,229)	(770,853)			(775,082)
Balance at ending at Dec. 31, 2019	$ 3,065,337	$ 1,212,803	$ 1,170,708	443,240	(1,494)	(6,559,880)	$ (580,358)		(1,249,644)
Balance at ending (in shares) at Dec. 31, 2019	2,750	1,000	1,170,708,112				201,548,643
Balance at beginning at Sep. 30, 2019	$ 3,043,259	$ 1,497,527	$ 1,107,308	78,155	(52)	(5,974,043)	$ (580,358)		(828,204)
Balance at beginning (in shares) at Sep. 30, 2019	2,750	1,250	1,107,307,740				201,548,643
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Preferred stock dividends declared	$ 22,078	$ 14,972				(53,014)			(15,964)
Conversions		$ (299,696)	$ 33,465	283,710					$ 17,479
Conversions (in shares)		(250)	33,465,590						55,916,667
Stock grants			$ 29,935	81,375					$ 111,310
Stock grants (in shares)			29,934,782
Shares acquired
Shares acquired (in shares)
Net loss					(1,442)	(532,823)			(534,265)
Balance at ending at Dec. 31, 2019	$ 3,065,337	$ 1,212,803	$ 1,170,708	$ 443,240	$ (1,494)	$ (6,559,880)	$ (580,358)		$ (1,249,644)
Balance at ending (in shares) at Dec. 31, 2019	2,750	1,000	1,170,708,112				201,548,643

NATURE OF OPERATIONS AND CONTIN

NATURE OF OPERATIONS AND CONTINUANCE OF BUSINESS	6 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS AND CONTINUANCE OF BUSINESS	1. NATURE OF OPERATIONS AND CONTINUANCE OF BUSINESS RedHawk Holdings Corp. was incorporated in the State of Nevada on November 30, 2005 under the name “Oliver Creek Resources Inc.” Effective August 12, 2008, we changed our name from “Oliver Creek Resources Inc.” to “Independence Energy Corp.” Effective October 13, 2015, by vote of a majority of the Company’s stockholders, the Company’s name was changed from “Independence Energy Corp.” to “RedHawk Holdings Corp.” Currently, the Company is a diversified holding company which, through our subsidiaries, is engaged in sales and distribution of medical devices, sales of branded generic pharmaceutical drugs, commercial real estate investment and leasing, sales of point of entry full-body security systems, and specialized financial services. Through its medical products business unit, the Company sells WoundClot Surgical - Advanced Bleeding Control, the SANDD™ Insulin Needle Destruction Unit (formerly known as the Disintegrator™), the Carotid Artery Digital Non-Contact Thermometer and Zonis ® Going Concern These financial statements have been prepared on a going concern basis, which implies that the Company will be able to continue as a going concern without further financing. The Company must continue to realize its assets to discharge its liabilities in the normal course of business. The Company has generated limited revenues to date and has never paid any dividends on its common stock and is unlikely to pay any common stock dividends or generate significant earnings in the immediate or foreseeable future. For the six month period ended December 31, 2019, the Company had revenues of $69,315, a consolidated net loss of $770,853 and cash of $832,870 used in operating activities. As of December 31, 2019, the Company had cash of $176,145, a certificate of deposit of $100,374, a working capital deficit of $632,166 and an accumulated deficit of $6,559,880. The continuation of the Company as a going concern is still dependent upon the continued financial support from its stockholders, the ability to raise equity or debt financing, cash proceeds from the sale of assets and the attainment of profitable operations from the Company’s businesses in order to discharge its obligations. We cannot predict, with certainty, the outcome of our efforts to generate liquidity and profitability, or whether such actions would generate the expected proceeds to the Company. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The unaudited interim condensed financial statements of the Company as of December 31, 2019 and for the three and six month periods ended December 31, 2019 and 2018 included herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The year-end condensed balance sheet dated as of June 30, 2019 is audited and is presented here as a basis for comparison. Although the financial statements and related information included herein have been prepared without audit, and certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, the Company believes that the note disclosures are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K as of June 30, 2019. In the opinion of our management, the unaudited interim financial statements included herein reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the Company’s financial position, results of operations, and cash flows for the periods presented. The results of operations for interim periods are not necessarily indicative of the results expected for the full year or any future period. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its subsidiaries in which we have a greater than 50% ownership. All material intercompany accounts have been eliminated upon consolidation. Equity investments, which we have an ownership greater than 20% but less than 50% through which we exercise significant influence over but do not control the investee and we are not the primary beneficiary of the investee’s activities, are accounted for using the equity method of accounting. Equity investments, which we have an ownership less than 20%, are recorded at cost. Use of Estimates The financial statements and related notes are prepared in conformity with GAAP which requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to valuation and impairment of investments, intangible assets, and long-lived assets, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Revenue Recognition In May 2014, the Financial Accounting Standards Board (which we refer to as the “FASB”) issued ASU 2014-19, Revenue from Contracts with Customers (ASU 2014-19). ASU 2014-19 established a single revenue recognition model for all contracts with customers, eliminates industry specific requirements and expands disclosure requirements. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, an entity should apply the following five steps: (1) identify contracts with customers, (2) identify the performance obligations in the contracts, (3) determine the transaction price, (4) allocate the transaction price to the performance obligation in the contract, and (5) recognize revenue as the entity satisfies performance obligations. Effective July 1, 2018, we adopted ASU 2014-19 using the modified retrospective method. The adoption of ASU 2014-19 did not have an impact on our consolidated financial statements but required enhanced footnote disclosures. See Note 3, Revenue Recognition, for additional information. We derive revenue from several types of activities – medical device sales, branded generic pharmaceutical sales, commercial real estate leasing and financial services. Our medical device sales include the marketing and distribution of certain professional and consumer grade digital non-contact thermometers, needle destruction unit and advanced bleeding control, non-compression hemostasis. Through our United Kingdom based subsidiary, we manufacture, and market, branded generic pharmaceuticals, and certain other generic pharmaceuticals known as “specials”. Our real estate leasing revenues are from certain commercial properties under lease. The financial service revenue is from brokerage services. The Company offers customer discounts in certain cases. Such discounts are estimated at time of product sale and revenues are reduced for such discounts at the time of the sale. Cash and Cash Equivalents We consider highly liquid investments with an original maturity of 90 days or less to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2019 or June 30, 2019. Accounts Receivable Accounts receivables are amounts due from customers of our pharmaceutical, medical device and financial services divisions. The amount is reported at the billed amount, net of any expected allowance for bad debts. There was no allowance for doubtful accounts as of December 31, 2019 or June 30, 2019. Inventory Inventory consist of purchased thermometers, an advanced bleeding control, non-compression hemostasis, a patented antimicrobial ionic silver calcium catheter dressing, needle destruction devices and certain branded generic pharmaceuticals held for resale. All inventories are stated at the lower of cost or net realizable value utilizing the first-in, first-out method. Property and Improvements Property and improvements are stated at cost. We provide for depreciation expense on a straight-line basis over each asset’s useful life depreciated to their estimated salvage value. Buildings are depreciated over a useful life of 20 to 30 years. Building improvements are depreciated over a useful life of 5 to 10 years. Our Louisiana real estate holdings include our former corporate headquarters on Chemin Metairie Road in Youngsville, Louisiana and a property on Jefferson Street in Lafayette, Louisiana. As of December 31, 2019, we are leasing both properties to third parties. The Company is also currently using the Chemin Metairie Road property for equipment storage for our real estate management unit. Effective August 1, 2017, the tenant that leases the Jefferson Street property renewed that lease through December 31, 2022 at a rent of $3,250 per month. Beginning December 1, 2019, the Chemin Metairie is leased through November 30, 2020 at a rental rate of $1,700 per month. Income Taxes Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted Accounting Standard Codification (which we refer to as “ASC”) 740, Income Taxes, Basic and Diluted Net Loss Per Share The Company computes net loss per share in accordance with ASC 260, Earnings Per Share, At December 31, 2019, including accrued but unpaid interest, there was one remaining 2016 Fixed Rate Convertible Note outstanding which totaling $60,301 and is convertible into 4,020,092 shares of common stock upon conversion of the remaining 2016 Fixed Rate Convertible Note. During the six months ended December 31, 2019, we issued in private offerings exempt from registration debt securities in the form of new 2019 Variable Rate Convertible Notes (See Note 7) in the amount of $578,125. The proceeds were used for working capital. The 2019 Variable Rate Convertible Notes are convertible into shares of common stock at a variable conversion rate. During the six months ended December 31, 2019, we issued in private offerings exempt from registration debt securities in the form of new 2019 Fixed Rate Convertible Notes (See Note 7) in the amount of $762,000. With the proceeds we paid off certain variable rate convertible notes outstanding in the amount of approximately $61,000, plus accrued interest. The 2019 Fixed Rate Convertible Notes mature on the fifth anniversary of the date of issuance and are convertible into shares of our common stock at a price of $0.015 per share and include 25% warrant coverage at $0.01 per share (which we refer to as the “2019 Warrants”). At December 31, 2019, including accrued but unpaid dividends, there were potentially 204,355,790 shares of common stock issuable upon the conversion of our outstanding Series A Preferred Stock and, including accrued but unpaid dividends, there were potentially 121,280,359 shares of common stock issuable upon the conversion of our outstanding Series B Preferred Stock. The shares of common stock to be issued upon conversion of the warrants and the shares issuable from the conversion of the notes and the Series A and Series B Preferred stock have been excluded from earnings per share calculations because these shares are anti-dilutive. On September 30, 2019, the Company received notice from the holder of $299,696 of the Series B Preferred Stock of his intent to convert his holdings into 29,969,648 shares of the Company’s common stock. The conversion was completed during the quarter ended December 31, 2019. During the fiscal year ended June 30, 2019, certain members of the board of directors and stockholders of the Company made $242,000 in interest free advances to the Company. During the six month period ended December 31, 2019, $10,000 of the advances were repaid and the remaining advances are convertible into shares of the Company’s common stock at rates ranging from $0.0024 to $0.0050 or 75,916,667 shares of common stock. During the quarter ended December 31, 2019, the Company received notice from related parties holding $142,000 of these advances of their intent to exercise their right to convert their advances into 55,916,667 shares of common stock. The conversion should be completed during the quarter ending March 31, 2020. Comprehensive Income (Loss) ASC 220, Comprehensive Income Financial Instruments Pursuant to ASC 820, Fair Value Measurements and Disclosures Level 1. Level 2. Level 3. The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable and accrued liabilities, debt, and amounts due to related parties. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. Leases In February 2016, the FASB issued ASU 2016-02, Leases Reclassification Certain amounts in prior periods have been reclassified to conform to the current period presentation.

REVENUE FROM CONTRACTS WITH CUS

REVENUE FROM CONTRACTS WITH CUSTOMERS	6 Months Ended
	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
REVENUE FROM CONTRACTS WITH CUSTOMERS	3. REVENUE FROM CONTRACTS WITH CUSTOMERS Revenue Recognition Sales of pharmaceuticals and medical devices are recognized generally at the point in time when delivery occurs and title transfers to the buyer. Sales of pharmaceuticals and medical devices are usually collected within 90 days of the date of sale. We have distributorship and sales representative agreements in place with third parties who do not take ownership of products. Any costs incurred related to these agreements are considered to be sales and marketing expenses. We also earn rental income which is recognized over time as the tenant occupies the space and pays the rental amount. Rentals are paid at the beginning of the month covered by the lease. Disaggregation of Revenue For the six and three month periods ended December 31, 2019 and 2018, a summary of our revenue on a disaggregated basis is as follows: Three Months Ended Six Months Ended December 31, December 31, 2019 2018 2019 2018 Sales of pharmaceuticals $ — $ 33,611 $ — $ 70,335 Sales of medical devices 1,904 482 42,712 676 Rental revenue from operating lease payments 16,853 14,759 26,603 24,509 $ 18,757 $ 48,852 $ 69,315 $ 95,520 Transaction Prices In some cases, we may offer introductory discounts to customers. In such cases, we reduce the recorded revenue for such discounts. For the six month periods ended December 31, 2019 and 2018, our revenues were reduced by $42,649 and $0, respectively, for such discounts. For the three month periods ended December 31, 2019 and 2018, our revenues were reduced by $28,109 and $0, respectively, for such discounts.

OTHER ASSETS

OTHER ASSETS	6 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
OTHER ASSETS	4. OTHER ASSETS The investment in Tower Hotel Fund 2013, LLC is recorded at cost and the Company is not aware of any indicator of impairment as of December 31, 2019. It is not practicable for the Company to estimate fair value of this investment. We are pursuing the sale of our remaining investment in the real estate limited partnership investment. During the year ended June 30, 2019, based on stability of operations of the underlying real estate property and recent valuations, the partnership refinanced the property. We received a distribution of approximately $370,000 from the real estate limited partnership following this refinancing. This distribution was recorded as a reduction of our investment in the limited partnership, which is recorded at cost. We are currently in negotiations to sell our interest in the partnership, but we are uncertain if such a transaction will close during the next twelve months. Thus, our investment is shown as a non-current asset as of December 31, 2019 in the accompanying consolidated balance sheet. As of December 31, 2019, we have approximately $352,620 ($269,980 net of accumulated amortization) in intangible assets related to licenses held by EcoGen. Such intangible assets are being amortized over an estimated useful life of 20 years. In September 2018, the Company acquired the exclusive license rights to certain medical device technology for $450,000, plus a broker’s fee of $17,500. Under the terms of the license agreement, the Company has paid $25,000 plus the first of a total twenty quarterly payments of $21,250. Any remaining payments become immediately payable upon the receipt of final approval by the FDA of devices related to the technology. Additionally, the Company agreed to pay a consulting fee of $1,000 per month for sixty months. The broker’s fee was paid through the issuance of 14 million shares of the Company’s common stock. The quarterly payments have been suspended at the present time as the Company and the seller negotiate certain disputes related to representations made by the seller at the time the Company acquired the rights. The ultimate date and resolution of this negotiation cannot be estimated at this time. As a result, the Company has included all of the future payments under the original agreement as noncurrent in the accompanying December 31, 2019 and June 30, 2019 consolidated balance sheets. In the six months ended December 31, 2019, we issued 20,000,000 shares of Common Stock under the terms of a 2015 consulting agreement as a result of reaching certain milestones related to the development of our needle destruction devices. Under the terms of this consulting agreement, an additional 40,000,000 shares of Common Stock may be issued if other milestones are met.

INSURANCE NOTE PAYABLE

INSURANCE NOTE PAYABLE	6 Months Ended
	Dec. 31, 2019
Loans Payable [Abstract]
INSURANCE NOTE PAYABLE	5. INSURANCE NOTE PAYABLE We finance a portion of our insurance premiums. At December 31, 2019, there was a $159,799 outstanding balance due on our premium finance agreements. The agreements have effective interest rates of 6.2% to 10.9%. The policies related to these premiums expire between July and October 2020.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	6. RELATED PARTY TRANSACTIONS Effective December 1, 2016, the Company entered into a $250,000 Commercial Note Line of Credit (which we refer to as the “Line of Credit”) with a stockholder and officer of the Company to evidence prior indebtedness and provide for future borrowings. The advances are used to fund our operations. The Line of Credit accrues interest at 5% per annum and matures on March 31, 2020. At maturity, or in connection with a pre-payment, subject to the conditions set forth in the Line of Credit, the stockholder has the right to convert the amount outstanding (or the amount of the prepayment) into the Company’s Series A Preferred Stock at the par value of $1,000 per share. At December 31, 2019, the outstanding principal balance totaled $0. During the fiscal year ended June 30, 2019, certain members of the board of directors and stockholders of the Company made $242,000 in interest free advances to the Company. During the six month period ended December 31, 2019, $10,000 of the advances were repaid and the remaining advances are convertible into shares of the Company’s common stock at rates ranging from $0.0024 to $0.0050 or 75,916,667 shares of common stock. During the quarter ended December 31, 2019, the Company received notice from the holders of $142,000 of these related parties of their intent to exercise their right to convert their advances into 55,916,667 shares of common stock. The conversion should be completed during the quarter ending March 31, 2020. Beginning in the quarter ended March 31, 2017, certain members of management agreed to forgo management fees in consideration of the operating cash flow needs of the Company. There is not a set timeline to reinstitute such management fees. As of December 31, 2019 and June 30, 2019, $50,000 in such fees remain unpaid and are recorded in accounts payable and accrued liabilities in the accompanying balance sheets.

LONG-TERM DEBT, DEBENTURES AND

LONG-TERM DEBT, DEBENTURES AND LINES OF CREDIT	6 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
LONG-TERM DEBT, DEBENTURES AND LINES OF CREDIT	7. LONG-TERM DEBT, DEBENTURES AND LINES OF CREDIT On November 12, 2015, we acquired certain commercial real estate from a related party that is an entity controlled by a stockholder and officer of the Company for $480,000 consisting of $75,000 of land costs and $405,000 of buildings and improvements. The purchase price was paid through the assumption by the Company of $265,000 of long-term bank indebtedness (which we refer to as “Note”) plus the issuance of 215 shares of the Company’s newly designated Series A Preferred Stock. The purchase price also included the cost of specific security improvements requested by the lessee. The Note is dated November 13, 2015 and has a principal amount of $265,000. Monthly payments under the Note are $1,962 including interest accruing at a rate of 5.95% per annum. The Note matures in June 2021 and is secured by the commercial real estate, guarantees by the Company and its real estate subsidiary and the personal guarantee of a stockholder who is also an officer of the Company. In March 2016, we authorized the issuance of up to $1 million in principal amount of convertible promissory notes (which we refer to as the “Fixed Rate Convertible Notes”). The Fixed Rate Convertible Notes are secured by certain Company real estate holdings. The 2016 Fixed Rate Convertible Notes mature on March 15, 2021, the fifth anniversary of the date of issuance and are convertible into shares of our common stock at a price of $0.015 per share. Interest accrues at a rate of 5% per annum and is payable semi-annually. The Company has the option to issue a notice of its intent to redeem, for cash, an amount equal to the sum of (a) 120% of the then outstanding principal balance, (b) accrued but unpaid interest and (c) all liquidated damages and other amounts due in respect of the Fixed Rate Convertible Notes. The Company may only issue the notice of its intent to redeem the Fixed Rate Convertible Notes if the trading average of the Company’s common stock equals or exceeds 300% of the conversion price during each of the five business days immediately preceding the date of the notice of intent to redeem. Holders of Fixed Rate Convertible Notes have the right to convert all or any portion of the Fixed Rate Convertible Notes at the conversion price at any time prior to redemption. During the year ended June 30, 2019, concurrent with the execution of the Exchange Agreement more fully described in Note 9, holders of $515,247 aggregate principal amount of the Company’s 5% convertible promissory notes (“Notes”), including accrued interest, converted their Notes into 103,132,226 shares of Common Stock. During the six month period ended December 31, 2019, $17,480 of Notes were converted by the holders into 3,495,943 shares of Common Stock. At December 31, 2019, there was one remaining 2016 Fixed Rate Convertible Note outstanding with principal and accrued interest approximates $60,301. The one remaining 2016 Fixed Rate Convertible Note (plus accrued interest) is convertible into our common stock at a conversion rate of $0.015 per share or 4,020,092 shares. During the six month period ended December 31, 2019 and 2018, we paid-in-kind $1,471 and $15,665, respectively, of interest on these convertible notes. In August 2019, we authorized the issuance of up to $1.25 million in principal amount of new convertible promissory notes (which we refer to as the “2019 Fixed Rate Convertible Notes”). The 2019 Fixed Rate Convertible Notes are secured by certain Company real estate holdings. As of December 31, 2019, $762,000 ($739,500 net of deferred loan costs) of 2019 Fixed Rate Convertible Notes were outstanding. The 2019 Fixed Rate Convertible Notes mature on the fifth anniversary of the date of issuance and are convertible into shares of our common stock at a price of $0.015 per share and include 25% warrant coverage at $0.01 per share (which we refer to as the “2019 Warrants”). Interest accrues at a rate of 7% per annum and is payable semi-annually. The Company has the option to issue a notice of its intent to redeem, for cash, an amount equal to the sum of (a) 120% of the then outstanding principal balance, (b) accrued but unpaid interest and (c) all liquidated damages and other amounts due in respect of the 2019 Fixed Rate Convertible Notes. The Company may only issue the notice of its intent to redeem the 2019 Fixed Rate Convertible Notes if the trading average of the Company’s common stock equals or exceeds 300% of the conversion price during each of the five business days immediately preceding the date of the notice of intent to redeem. The holder of the 2019 Fixed Rate Convertible Notes has the right to convert all or any portion of the 2019 Fixed Rate Convertible Notes at the conversion price at any time prior to redemption. During the six months ended December 31, 2019, we also issued $578,125 of convertible notes to third parties with variable conversion rates (“2019 Variable Rate Convertible Notes”). The 2019 Variable Rate Convertible Notes mature at various dates between September 2020 and December 2020. We received, net of financing costs incurred, $505,696 in cash from the issuance of these notes. These 2019 Variable Rate Convertible Notes have interest accruing at rates ranging between 10% - 12%. These notes issued to third parties have a variable conversion rate based on the price of the Company’s common stock. None of the 2019 Variable Rate Convertible Notes have been converted into shares of common stock. During the quarter ended September 30, 2019, a holder of certain Variable Rate Convertible Notes issued in February 2018 converted $41,250 of notes, including accrued interest, into 41,250,000 shares of common stock as part of a settlement agreement between the parties. At December 31, 2019, $243,125 of the 2019 Variable Rate Convertible Notes were convertible into common stock beginning in the quarter ending March 31, 2020. Subsequent to December 31, 2019, we repaid in full the entire outstanding principal amount of $243,125, plus accrued interest, under these 2019 Variable Convertible Notes. Certain of the 2019 Variable Rate Convertible Notes have maturity dates prior to December 31, 2020 and could be classified as a current liability. However, it is the Company’s expectation that we will either re-finance these convertible notes to longer terms, pay off such amounts with the proceeds of long-term financing, or permit a limited amount of conversions. Therefore, we have classified these notes as noncurrent. If we do not re-finance these convertible notes to longer terms, however, the holders of the convertible notes have the option to convert these notes into equity or hold the convertible notes to maturity. During the year ended June 30, 2019, we issued $29,250 of convertible notes to our majority stockholder in exchange for 7,450,000 shares of our common stock. In February 2018, we obtained a $100,000 line of credit from a bank. The line of credit matures in February 2021 and is collateralized by a $100,000 certificate of deposit at the bank. As of December 31, 2019, approximately $100,000 was drawn under the line of credit. The interest rate on the line of credit is 7.0% per annum. Subsequent to December 31, 2019, proceeds from the certificate of deposit were used to repay the outstanding balance under the line of credit plus accrued interest. On March 12, 2019, we obtained a $180,000 real estate loan from a financial institution. The note matures on April 1, 2020 and is secured by certain real estate property and the personal guarantee of an officer and director of the Company. Interest only is payable monthly and accrues at an interest rate of 12%. In the quarter ended June 30, 2019, we entered into a series of credit financing arrangements from financing institutions by pledging future accounts receivable. The proceeds from these credit agreements were used to pay the initial amount due under the Schreiber settlement agreement. As of June 30, 2019, we had drawn approximately $153,000 under these agreements. During the six month period ended December 31, 2019, additional draws of approximately $6,000 occurred and payments of approximately $56,000 were made. As of December 31, 2019, approximately $103,000 remained outstanding on these loans.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	8. COMMITMENTS AND CONTINGENCIES Schreiber Litigation On January 31, 2017, the Company and Beechwood Properties, LLC (“Beechwood”) filed suit against Daniel J. Schreiber (“Mr. Schreiber”) and the Daniel J. Schreiber Living Trust – Dtd 2/08/95 (“Schreiber Trust”) in the United States District Court for the Eastern District of Louisiana (the “Louisiana Court”) under Civil Action No. 2:2017cv819-B(3) (the “Louisiana Lawsuit”). Mr. Schreiber and the Schreiber Trust answered the Louisiana Lawsuit and counter-claimed against the Company and Beechwood and made additional claims against Mr. G. Darcy Klug (“Mr. Klug”) in the Louisiana Lawsuit. Mr. Klug is an officer and director of RedHawk and is sole owner of Beechwood. Mr. Klug also holds voting control of RedHawk. On April 24, 2017, Mr. Schreiber and the Schreiber Trust also filed suit against the Company, Mr. Klug and six (6) other defendants in the United States District Court for the Southern District of California under Civil Action No. 3:17-cv-00824-WQH-BLM which case was dismissed without prejudice on September 26, 2017 (the “California Lawsuit” and along with the Louisiana Lawsuit, the “Litigations”). On March 22, 2019, the parties to the Litigations have entered into a Settlement Agreement and General Release (“Settlement Agreement”) to resolve all issues arising out of the subject matter of the Litigation. In consideration of the mutual promises, covenants and conditions contained in the Settlement Agreement, the parties to the Litigation agreed that (i) Mr. Schreiber and the Schreiber Trust shall transfer all Company stock they presently own (52,377,108 common shares) to the Company and (ii) the Company shall (a) make to Mr. Schreiber and the Schreiber Trust a cash payment of Two Hundred Fifty Thousand and 00/100 Dollars (US$250,000.00) and (b) issue two Promissory Notes, each in the principal amount of Two Hundred Thousand and 00/100 Dollars (US$200,000.00), one of which shall be due and payable on or before September 6, 2020 and the other shall be due and payable on or before September 5, 2021. As a result of this Settlement Agreement, we have recorded a loss of $471,880 in the year ended June 30, 2019. Each Promissory Note shall be non-interest bearing, however each (i) shall bear a $15,000 late penalty if the principal amount is not repaid by the due date and (ii) shall bear interest at a rate of 18% per annum, from the issue date, if the principal is not repaid by the 30th date after the due date. Pursuant to a Security Agreement between the parties, Mr. Klug and Beechwood secured the Company’s obligations to the Schreiber Trust under the Settlement Agreement by granting first-priority security interests in (i) 1,000 shares of Mr. Klug’s Series B Preferred Company Stock; and 1,473 shares of Mr. Klug’s Series A Preferred Company Stock, and (ii) Beechwood’s interest in the Tower Hotels Fund 2014, LLC. On October 11, 2019, Mr. Schreiber and the Schreiber Trust filed a Motion to Enforce Settlement Agreement (the “Motion”) with the Louisiana Court alleging that the Company has failed to comply with its obligations under the Settlement Agreement by selling stock for cash subsequent to the parties entering into the Settlement Agreement. The Motion seeks to accelerate the amounts owed to Mr. Schreiber and the Schreiber Trust under the Settlement Agreement as well as attorneys’ fees. The Company believes the Motion is without merit and intends to vigorously defend against the Motion. Consultant Agreement On July 19, 2019 (the “Effective Date”), RedHawk Holdings Corp. (the “Company”) and its wholly-owned subsidiary, RedHawk Medical Products & Services, along with other affiliated entities, entered into a Consultant Agreement (“Agreement”) with Drew Pinsky, Inc (“DPI”) f/s/o Dr. Drew Pinsky (“Consultant”), for Consultant to be the exclusive spokesperson for the Company’s Sharps Needle and Destruction Device (“ SAN SAN Under the Agreement, the Company will pay DPI a royalty equal to 3% of the “Net Sales”, as defined in the Agreement, of the Products but in no event will the royalty be less than $3.50 per SAN SAN Pursuant to the Agreement, the Company agreed to issue to the Consultant 68,700,000 shares of the Company’s common stock, which is equal to approximately 5% of the Company’s outstanding common stock on a fully diluted basis as of the Effective Date. Further, the Company has agreed to issue to the Consultant, one year after the Effective Date, an additional 68,700,000 shares of the Company’s common stock, unless DPI has provided the Company with written notice of its intention not to extend the Initial Period. As of the date of this Quarterly Report on Form 10-Q, the Company has not yet issued any of shares pursuant to the Agreement.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	6 Months Ended
	Dec. 31, 2019
Equity [Abstract]
STOCKHOLDERS' EQUITY	9. STOCKHOLDERS’ EQUITY On August 20, 2018, by a vote of the majority of our stockholders, we increased the number of our authorized shares from 1,000,000,000 to 2,000,000,000. Preferred Stock Pursuant to a certificate of designation filed with the Secretary of State of the State of Nevada, effective November 12, 2015, 2,750 shares of our authorized Preferred Stock have been designated as Series A 5% Convertible Preferred Stock, originally with a $1,000 stated value (which we refer to as “Series A Preferred Stock”). The holders of the Series A Preferred Stock are entitled to receive cumulative dividends at a rate of 5% per annum, payable quarterly in cash, or at the Company’s option, such dividends shall be accreted to, and increase, the stated value of the issued Series A Preferred Stock (which we refer to as “PIK”). Holders of the Series A Preferred Stock are entitled to votes on all matters submitted to stockholders at a rate of ten votes for each share of common stock into which the Series A Preferred Stock may be converted. After six months from issuance, each share of Series A Preferred Stock is convertible, at the option of the holder, into the number of shares of common stock equal to the quotient of the stated value, as adjusted for PIK dividends, by $0.015, as adjusted for stock splits and dividends. Pursuant to a certificate of designation filed with the Secretary of State of the State of Nevada, effective February 16, 2016, 1,250 shares of our authorized Preferred Stock have been designated as Series B 5% Convertible Preferred Stock, originally with a $1,000 stated value (which we refer to as “Series B Preferred Stock”). The holders of the Series B Preferred Stock are entitled to receive cumulative dividends at a rate of 5% per annum, payable quarterly in cash, or at the Company’s option, such dividends shall be accreted to, and increase, the stated value of the issued Series B Preferred Stock (which we refer to as “PIK”). Holders of the Series B Preferred Stock are entitled to votes on all matters submitted to stockholders at a rate of ten votes for each share of common stock into which the Series B Preferred Stock may be converted. After six months from issuance, each share of Series B Preferred Stock is convertible, at the option of the holder, into the number of shares of common stock equal to the quotient of the stated value, as adjusted for PIK dividends, by $0.01, as adjusted for stock splits and dividends. During the six months ended December 31, 2019 and 2018, we paid-in-kind $114,591 and $77,160, respectively, of related preferred stock dividends. Exchange Agreement On June 20, 2019, RedHawk Holdings Corp. entered into a Stock Exchange Agreement (“Exchange Agreement”) with Beechwood. G. Darcy Klug, the Company’s Chairman of the Board, Interim Chief Executive Officer and Chief Financial Officer, is the sole member and manager of Beechwood. Under the Exchange Agreement, the Company purchased from Beechwood 113,700,000 shares of the Company’s common stock, $0.001 par value per share (“Common Stock”), in exchange for 1,277 shares of the Company’s 5% Series A Preferred Stock and a Stock Purchase Warrant (“Warrant”) to acquire 113,508,450 shares of Common Stock at an exercise price of $0.005 per share (collectively, the “Transactions”). The Warrant expires June 20, 2029. Concurrent with the execution of the Exchange Agreement, holders of $580,108 aggregate principal amount of the Company’s 5% convertible promissory notes (“Notes”), including accrued interest, were offered and converted their Notes into 116,021,700 shares of Common Stock at a conversion price of $0.005 per share. The extinguishment of the notes and the related accrued interest for the shares of common stock resulted in a gain on extinguishment of approximately $419,000 based on the closing price of the common stock as of the exchange date. Holders of the Series A Preferred Stock are entitled to receive cumulative dividends at a rate of 5% per annum, payable quarterly in cash, or at the Company’s option, such dividends shall be accreted to, and increase, the stated value of the issued Series A Preferred Stock (“PIK dividends”). Holders of the Series A Preferred Stock are entitled to votes on all matters submitted to stockholders at a rate of ten votes for each share of common stock into which the Series A Preferred Stock may be converted. After six months from issuance, each share of Series A Preferred Stock is convertible, at the option of the holder, into the number of shares of Common Stock equal to the quotient of the stated value, as adjusted for PIK dividends, by $0.015, as adjusted for stock splits and dividends. Warrants In conjunction with the Exchange Agreement, Beechwood was issued 113,508,450 warrants to purchase the Company’s common stock at a price of $0.005 per share. The warrants expire in June 2029 and are assignable. In conjunction with the 2019 Fixed Rate Convertible Notes, the holders of the 2019 Fixed Rate Convertible Notes were issued 19,050,000 warrants to purchase the Company’s common stock at a price of $0.01 per share. The warrants expire ten years from the date of issuance.

INCOME TAXES

INCOME TAXES	6 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
INCOME TAXES	10. INCOME TAXES As of June 30, 2019, the Company had approximately $5 million of U.S. net operating losses (NOLs) carried forward to offset taxable income in future years. Approximately $4 million of this NOL will expire commencing in fiscal 2026 and run through 2038. The NOLs of approximately $1 million from the year ended June 30, 2019 has an indefinite carryforward period. As a result of the numerous common stock transactions that have occurred, the amount of these NOLs which is actually available to offset future income may be severely limited due to change-in-control tax provisions. The Company has not estimated the effect of such change-in-control limitation. The related deferred income tax asset of these NOLs, without consideration of any change-of-control limitation, was estimated to be approximately $750,000 as of June 30, 2019. As a result of the enactment of the Tax Cuts and Jobs Act (The Act) in December 31, 2017, the estimated deferred income tax asset related to U.S. NOL carry forwards is based on the reduced 21% corporate income tax rate. Due to our history of operating losses and the uncertainty surrounding the realization of the deferred tax assets in future years, our management has determined that it is more likely than not that the deferred tax assets will not be realized in future periods. Accordingly, the Company has recorded a valuation allowance against its net deferred tax assets. Thus, there is no net tax asset recorded as of December 31, 2019 or June 30, 2019 as a 100% valuation allowance has been established for any tax benefit. Similarly, there is no income tax benefit recorded on the net loss of the Company for the periods ended December 31, 2019 and 2018.

SEGMENT INFORMATION

SEGMENT INFORMATION	6 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
SEGMENT INFORMATION	11. SEGMENT INFORMATION SFAS No. 131, “Disclosures About Segments of an Enterprise and Related Information,” MEDICAL Six months ended LAND & DEVICE & OTHER December 31, 2019 HOSPITALITY PHARMA SERVICES CORPORATE TOTAL Operating revenues $ 26,603 $ 42,712 $ — $ — $ 69,315 Operating loss $ (15,976 ) $ (197,610 ) $ (75 ) $ (390,204 ) $ (603,865 ) Interest expense $ 26,569 $ 317 $ — $ 184,629 $ 211,515 Depreciation and amortization $ 15,667 $ 26,250 $ — $ — $ 41,917 Identifiable assets $ 919,515 $ 201,189 $ 77,849 $ 1,467,089 $ 2,665,642 MEDICAL Six months ended LAND & DEVICE & OTHER December 31, 2018 HOSPITALITY PHARMA SERVICES CORPORATE TOTAL Operating revenues $ 24,509 $ 71,011 $ — $ — $ 95,520 Operating income (loss) $ (2,203 ) $ (84,761 ) $ (201 ) $ (233,663 ) $ (320,828 ) Interest expense $ 7,737 $ — $ — $ 173,481 $ 181,218 Depreciation and amortization $ 15,667 $ 45,484 $ — $ — $ 61,151 Identifiable assets $ 943,966 $ 1,117,450 $ — $ 162,129 $ 2,223,545 MEDICAL Three months ended LAND & DEVICE & OTHER December 31, 2019 HOSPITALITY PHARMA SERVICES CORPORATE TOTAL Operating revenues $ 16,853 $ 1,904 $ — $ — $ 18,757 Operating loss $ (10,501 ) $ (130,313 ) $ (75 ) $ (268,291 ) $ (409,180 ) Interest expense $ 12,891 $ 212 $ — $ 110,540 $ 123,643 Depreciation and amortization $ 7,833 $ 13,126 $ — $ — $ 20,959 MEDICAL Three months ended LAND & DEVICE & OTHER December 31, 2018 HOSPITALITY PHARMA SERVICES CORPORATE TOTAL Operating revenues $ 14,759 $ 34.093 $ — $ — $ 48,852 Operating income (loss) $ 3,285 $ (34,335 ) $ (21 ) $ (181,743 ) $ (212,814 ) Interest expense $ 3,841 $ — $ — $ 88,774 $ 92,615 Depreciation and amortization $ 7,834 $ 22,568 $ — $ — $ 30,402

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	12. SUBSEQUENT EVENTS The Company evaluated events occurring after December 31, 2019, and through the date the financial statements were issued, February 19, 2020 and concluded there were no events or transactions that would require recognition or disclosure in these financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The unaudited interim condensed financial statements of the Company as of December 31, 2019 and for the three and six month periods ended December 31, 2019 and 2018 included herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The year-end condensed balance sheet dated as of June 30, 2019 is audited and is presented here as a basis for comparison. Although the financial statements and related information included herein have been prepared without audit, and certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, the Company believes that the note disclosures are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K as of June 30, 2019. In the opinion of our management, the unaudited interim financial statements included herein reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the Company’s financial position, results of operations, and cash flows for the periods presented. The results of operations for interim periods are not necessarily indicative of the results expected for the full year or any future period.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its subsidiaries in which we have a greater than 50% ownership. All material intercompany accounts have been eliminated upon consolidation. Equity investments, which we have an ownership greater than 20% but less than 50% through which we exercise significant influence over but do not control the investee and we are not the primary beneficiary of the investee’s activities, are accounted for using the equity method of accounting. Equity investments, which we have an ownership less than 20%, are recorded at cost.
Use of Estimates	Use of Estimates The financial statements and related notes are prepared in conformity with GAAP which requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to valuation and impairment of investments, intangible assets, and long-lived assets, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
Revenue Recognition	Revenue Recognition In May 2014, the Financial Accounting Standards Board (which we refer to as the “FASB”) issued ASU 2014-19, Revenue from Contracts with Customers (ASU 2014-19). ASU 2014-19 established a single revenue recognition model for all contracts with customers, eliminates industry specific requirements and expands disclosure requirements. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, an entity should apply the following five steps: (1) identify contracts with customers, (2) identify the performance obligations in the contracts, (3) determine the transaction price, (4) allocate the transaction price to the performance obligation in the contract, and (5) recognize revenue as the entity satisfies performance obligations. Effective July 1, 2018, we adopted ASU 2014-19 using the modified retrospective method. The adoption of ASU 2014-19 did not have an impact on our consolidated financial statements but required enhanced footnote disclosures. See Note 3, Revenue Recognition, for additional information. We derive revenue from several types of activities – medical device sales, branded generic pharmaceutical sales, commercial real estate leasing and financial services. Our medical device sales include the marketing and distribution of certain professional and consumer grade digital non-contact thermometers, needle destruction unit and advanced bleeding control, non-compression hemostasis. Through our United Kingdom based subsidiary, we manufacture, and market, branded generic pharmaceuticals, and certain other generic pharmaceuticals known as “specials”. Our real estate leasing revenues are from certain commercial properties under lease. The financial service revenue is from brokerage services. The Company offers customer discounts in certain cases. Such discounts are estimated at time of product sale and revenues are reduced for such discounts at the time of the sale.
Cash and Cash Equivalents	Cash and Cash Equivalents We consider highly liquid investments with an original maturity of 90 days or less to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2019 or June 30, 2019.
Accounts Receivable	Accounts Receivable Accounts receivables are amounts due from customers of our pharmaceutical, medical device and financial services divisions. The amount is reported at the billed amount, net of any expected allowance for bad debts. There was no allowance for doubtful accounts as of December 31, 2019 or June 30, 2019.
Inventory	Inventory Inventory consist of purchased thermometers, an advanced bleeding control, non-compression hemostasis, a patented antimicrobial ionic silver calcium catheter dressing, needle destruction devices and certain branded generic pharmaceuticals held for resale. All inventories are stated at the lower of cost or net realizable value utilizing the first-in, first-out method.
Property and Improvements	Property and Improvements Property and improvements are stated at cost. We provide for depreciation expense on a straight-line basis over each asset’s useful life depreciated to their estimated salvage value. Buildings are depreciated over a useful life of 20 to 30 years. Building improvements are depreciated over a useful life of 5 to 10 years. Our Louisiana real estate holdings include our former corporate headquarters on Chemin Metairie Road in Youngsville, Louisiana and a property on Jefferson Street in Lafayette, Louisiana. As of December 31, 2019, we are leasing both properties to third parties. The Company is also currently using the Chemin Metairie Road property for equipment storage for our real estate management unit. Effective August 1, 2017, the tenant that leases the Jefferson Street property renewed that lease through December 31, 2022 at a rent of $3,250 per month. Beginning December 1, 2019, the Chemin Metairie is leased through November 30, 2020 at a rental rate of $1,700 per month
Income Taxes	Income Taxes Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted Accounting Standard Codification (which we refer to as “ASC”) 740, Income Taxes,
Basic and Diluted Net Loss Per Share	Basic and Diluted Net Loss Per Share The Company computes net loss per share in accordance with ASC 260, Earnings Per Share, At December 31, 2019, including accrued but unpaid interest, there was one remaining 2016 Fixed Rate Convertible Note outstanding which totaling $60,301 and is convertible into 4,020,092 shares of common stock upon conversion of the remaining 2016 Fixed Rate Convertible Note. During the six months ended December 31, 2019, we issued in private offerings exempt from registration debt securities in the form of new 2019 Variable Rate Convertible Notes (See Note 7) in the amount of $578,125. The proceeds were used for working capital. The 2019 Variable Rate Convertible Notes are convertible into shares of common stock at a variable conversion rate. During the six months ended December 31, 2019, we issued in private offerings exempt from registration debt securities in the form of new 2019 Fixed Rate Convertible Notes (See Note 7) in the amount of $762,000. With the proceeds we paid off certain variable rate convertible notes outstanding in the amount of approximately $61,000, plus accrued interest. The 2019 Fixed Rate Convertible Notes mature on the fifth anniversary of the date of issuance and are convertible into shares of our common stock at a price of $0.015 per share and include 25% warrant coverage at $0.01 per share (which we refer to as the “2019 Warrants”). At December 31, 2019, including accrued but unpaid dividends, there were potentially 204,355,790 shares of common stock issuable upon the conversion of our outstanding Series A Preferred Stock and, including accrued but unpaid dividends, there were potentially 121,280,359 shares of common stock issuable upon the conversion of our outstanding Series B Preferred Stock. The shares of common stock to be issued upon conversion of the warrants and the shares issuable from the conversion of the notes and the Series A and Series B Preferred stock have been excluded from earnings per share calculations because these shares are anti-dilutive. On September 30, 2019, the Company received notice from the holder of $299,696 of the Series B Preferred Stock of his intent to convert his holdings into 29,969,648 shares of the Company’s common stock. The conversion was completed during the quarter ended December 31, 2019. During the fiscal year ended June 30, 2019, certain members of the board of directors and stockholders of the Company made $242,000 in interest free advances to the Company. During the six month period ended December 31, 2019, $10,000 of the advances were repaid and the remaining advances are convertible into shares of the Company’s common stock at rates ranging from $0.0024 to $0.0050 or 75,916,667 shares of common stock. During the quarter ended December 31, 2019, the Company received notice from related parties holding $142,000 of these advances of their intent to exercise their right to convert their advances into 55,916,667 shares of common stock. The conversion should be completed during the quarter ending March 31, 2020.
Comprehensive Income (Loss)	Comprehensive Income (Loss) ASC 220, Comprehensive Income
Financial Instruments	Financial Instruments Pursuant to ASC 820, Fair Value Measurements and Disclosures Level 1. Level 2. Level 3. The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable and accrued liabilities, debt, and amounts due to related parties. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.
Leases	Leases In February 2016, the FASB issued ASU 2016-02, Leases
Reclassification	Reclassification Certain amounts in prior periods have been reclassified to conform to the current period presentation.

REVENUE FROM CONTRACTS WITH C_2

REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)	6 Months Ended
	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Schedule of disaggregation of revenue	For the six and three month periods ended December 31, 2019 and 2018, a summary of our revenue on a disaggregated basis is as follows: Three Months Ended Six Months Ended December 31, December 31, 2019 2018 2019 2018 Sales of pharmaceuticals $ — $ 33,611 $ — $ 70,335 Sales of medical devices 1,904 482 42,712 676 Rental revenue from operating lease payments 16,853 14,759 26,603 24,509 $ 18,757 $ 48,852 $ 69,315 $ 95,520

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	6 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Schedule of segment activity	The following table reflects our segments as of December 31, 2019 and 2018 and for the six month and three month then ended. MEDICAL Six months ended LAND & DEVICE & OTHER December 31, 2019 HOSPITALITY PHARMA SERVICES CORPORATE TOTAL Operating revenues $ 26,603 $ 42,712 $ — $ — $ 69,315 Operating loss $ (15,976 ) $ (197,610 ) $ (75 ) $ (390,204 ) $ (603,865 ) Interest expense $ 26,569 $ 317 $ — $ 184,629 $ 211,515 Depreciation and amortization $ 15,667 $ 26,250 $ — $ — $ 41,917 Identifiable assets $ 919,515 $ 201,189 $ 77,849 $ 1,467,089 $ 2,665,642 MEDICAL Six months ended LAND & DEVICE & OTHER December 31, 2018 HOSPITALITY PHARMA SERVICES CORPORATE TOTAL Operating revenues $ 24,509 $ 71,011 $ — $ — $ 95,520 Operating income (loss) $ (2,203 ) $ (84,761 ) $ (201 ) $ (233,663 ) $ (320,828 ) Interest expense $ 7,737 $ — $ — $ 173,481 $ 181,218 Depreciation and amortization $ 15,667 $ 45,484 $ — $ — $ 61,151 Identifiable assets $ 943,966 $ 1,117,450 $ — $ 162,129 $ 2,223,545 MEDICAL Three months ended LAND & DEVICE & OTHER December 31, 2019 HOSPITALITY PHARMA SERVICES CORPORATE TOTAL Operating revenues $ 16,853 $ 1,904 $ — $ — $ 18,757 Operating loss $ (10,501 ) $ (130,313 ) $ (75 ) $ (268,291 ) $ (409,180 ) Interest expense $ 12,891 $ 212 $ — $ 110,540 $ 123,643 Depreciation and amortization $ 7,833 $ 13,126 $ — $ — $ 20,959 MEDICAL Three months ended LAND & DEVICE & OTHER December 31, 2018 HOSPITALITY PHARMA SERVICES CORPORATE TOTAL Operating revenues $ 14,759 $ 34.093 $ — $ — $ 48,852 Operating income (loss) $ 3,285 $ (34,335 ) $ (21 ) $ (181,743 ) $ (212,814 ) Interest expense $ 3,841 $ — $ — $ 88,774 $ 92,615 Depreciation and amortization $ 7,834 $ 22,568 $ — $ — $ 30,402

NATURE OF OPERATIONS AND CONT_2

NATURE OF OPERATIONS AND CONTINUANCE OF BUSINESS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Gross revenues
Net of discounts on gross revenues			69,315
Consolidated net loss	$ 532,823	$ 701,929	770,853	$ 898,546
Net cash used in operating activities			832,870	304,406
Cash	176,145	$ 14,768	176,145	$ 14,768	$ 1,648	$ 19,034
Certificate of deposit	100,374		100,374
Working capital	632,166		632,166
Accumulated deficit	$ (6,559,880)		$ (6,559,880)		$ (5,674,436)

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019
Warrant outstanding		113,508,450		113,508,450
Exercise price of warrants (in dollars per share)		$ 0.005		$ 0.005
Convertible notes, amount		$ 578,125		$ 578,125
Number of conversion shares issued (in shares)		55,916,667
Converted instrument amount		$ 17,479	$ 21,250	72,791	$ 156,190
Advances from related parties		$ 142,000		$ 142,000
Common Stock par value (in dollars per shares)		$ 0.001		$ 0.001		$ 0.001
Board Of Directors And Stockholders [Member]
Number of conversion shares issued (in shares)				75,916,667
Repayment of debt				$ 10,000
Advances from related parties		$ 10,000		$ 10,000		$ 242,000
Description of stock conversion				Remaining advances are convertible into shares of the Company’s common stock at rates ranging from $0.0024 to $0.0050 or 75,916,667 shares of common stock.
2016 Fixed Rate Convertible Notes [Member]
Number of conversion shares issued (in shares)				4,020,092
Accrued but unpaid interest		$ 60,301		$ 60,301
2016 Fixed Rate Convertible Notes [Member] | Warrant [Member]
Equity method ownership percentage		25.00%		25.00%
Warrant outstanding		0.01		0.01
2019 Fixed Rate Convertible Notes [Member]
Fixed rate convertible outstanding		$ 762,000		$ 762,000
Common Stock par value (in dollars per shares)		$ 0.015		$ 0.015
Variable Rate Convertible Notes [Member]
Repayment of debt				$ 61,000
New 2019 Variable Rate Convertible Notes [Member]
Aggregate principal amount		$ 578,125		$ 578,125
Minimum [Member]
Equity method ownership percentage		20.00%		20.00%
Maximum [Member]
Equity method ownership percentage		50.00%		50.00%
Building [Member] | Minimum [Member]
Useful life				20 years
Building [Member] | Maximum [Member]
Useful life				30 years
Building Improvements [Member] | Minimum [Member]
Useful life				5 years
Building Improvements [Member] | Maximum [Member]
Useful life				10 years
Jefferson Street Property [Member ]
Rental rate per month				$ 3,250
Renewed lease term				Dec. 31, 2022
Chemin Metairie Road [Member]
Rental rate per month				$ 1,700
Renewed lease term				Nov. 30, 2020
SERIES A PREFERRED STOCK [Member]
Incremental common shares issuable upon conversion of preferred stock				204,355,790
Number of conversion shares issued (in shares)
Converted instrument amount
SERIES B PREFERRED STOCK [Member]
Incremental common shares issuable upon conversion of preferred stock				121,280,359
Number of conversion shares issued (in shares)	29,969,648	(250)		(250)
Converted instrument amount	$ 299,696	$ (299,696)		$ (299,696)

REVENUE FROM CONTRACTS WITH C_3

REVENUE FROM CONTRACTS WITH CUSTOMERS (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Disaggregation of revenue	$ 18,757	$ 48,852	$ 69,315	$ 95,520
Sales Of Pharmaceuticals [Member]
Disaggregation of revenue		33,611		70,335
Sales Of Medical Devices [Member]
Disaggregation of revenue	1,904	482	42,712	676
Rental Revenue From Operating Lease Payments [Member]
Disaggregation of revenue	$ 16,853	$ 14,759	$ 26,603	$ 24,509

REVENUE FROM CONTRACTS WITH C_4

REVENUE FROM CONTRACTS WITH CUSTOMERS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Date of sale			90 days
Transaction prices	$ 28,109	$ 0	$ 42,649	$ 0

OTHER ASSETS (Details Narrative

OTHER ASSETS (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019
Intangible assets related to licenses		$ 816,094		$ 816,094		$ 848,992
Net of accumulated amortization		431,196		431,196		$ 404,946
EcoGen [Member]
Intangible assets related to licenses		352,620		352,620
Net of accumulated amortization		$ 269,980		$ 269,980
Intangible assets, useful life				20 years
Chemin Metairie Road [Member]
Distribution received from real estate partnership				$ 370,000
License Agreement [Member]
Payments to acquire license rights	$ 21,250
Common Stock [Member]
Number of shares issued		29,934,782	29,400,000	49,934,782	29,400,000
Common Stock [Member] | Consulting Agreement [Member]
Number of shares issued				20,000,000
Common Stock [Member] | Consulting Agreement [Member]
Number of shares issued				40,000,000
September 2018 [Member]
Payments to acquire license rights	$ 25,000
Total number quarterly payments	Twenty
September 2018 [Member] | Developed Technology Rights [Member]
Payments to acquire license rights	$ 450,000
Consulting fee	1,000
Broker's fee	$ 17,500
September 2018 [Member] | Common Stock [Member]
Number of shares issued	14,000,000

INSURANCE NOTE PAYABLE (Details

INSURANCE NOTE PAYABLE (Details Narrative) - USD ($)	6 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Insurance notes payable	$ 159,799	$ 136,859
Description of the maturity date	July and October 2020
Minimum [Member]
Interest rates	6.20%
Maximum [Member]
Interest rates	10.90%

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Jan. 01, 2020	Feb. 28, 2018	Dec. 31, 2019	Jun. 30, 2019	Dec. 01, 2016
Line of credit interest rate			7.00%
Line of credit maturity date		Feb. 28, 2021
Due to related party			$ 242,000	$ 230,250
Accounts payable and accrued liabilities			50,000	50,000
Advances from related parties			$ 142,000
Minimum [Member]
Conversion rate			$ 0.0024
Maximum [Member]
Conversion rate			$ 0.0050
Board Of Directors And Stockholders [Member]
Conversion of common stock issued			75,916,667
Advances from related parties			$ 10,000	$ 242,000
Commercial Note Line of Credit [Member]
Due to related party			$ 0
Related Party [Member] | Subsequent Event [Member]
Conversion of common stock issued	55,916,667
Advances from related parties	$ 142,000
Line of Credit [Member] | Stockholder and Officer [Member]
Commercial note line of credit					$ 250,000
Line of credit interest rate			5.00%
Line of credit maturity date			Mar. 31, 2020
Line of Credit [Member] | SERIES A PREFERRED STOCK [Member] | Stockholder and Officer [Member]
Preferred stock, stated value (in dollars per share)			$ 1,000

LONG-TERM DEBT, DEBENTURES AN_2

LONG-TERM DEBT, DEBENTURES AND LINES OF CREDIT (Details Narrative) - USD ($)	Mar. 12, 2019	Feb. 28, 2018	Nov. 13, 2015	Nov. 12, 2015	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jan. 01, 2020
Description of maturity							July and October 2020
Net of financing costs					$ 505,696		$ 505,696
Interest paid in kind							1,471	$ 15,665
Line of credit outstanding		$ 100,000			203,307		203,307		$ 253,219
Line of credit, maturity date		Feb. 28, 2021
Line of credit, additional draws							6,000
Line of credit, collateral value		$ 100,000					56,000
Line of credit withdrawn					$ 100,000		$ 100,000
Line of credit interest rate							7.00%
Number of shares issued on conversion					55,916,667
Accrued interest					$ 50,000		$ 50,000		50,000
Real Estate Loan [Member] | Financial Institution [Member]
Convertible promissory note principal	$ 180,000
Convertible promissory notes interest rate	12.00%
Debt maturity date	Apr. 1, 2020
Line of credit withdrawn									$ 153,000
Remaining outstanding amount on loans							$ 103,000
Minimum [Member]
Common stock conversion price | $ / shares					$ 0.0024		$ 0.0024
Maximum [Member]
Common stock conversion price | $ / shares					$ 0.0050		$ 0.0050
SERIES A PREFERRED STOCK [Member]
Number of shares issued on conversion
Number of share issued				215
Land [Member]
Payment to acquired real estate from a related party				$ 75,000
Building and Improvements [Member]
Payment to acquired real estate from a related party				405,000
Stockholder and Officer [Member]
Payment to acquired real estate from a related party				480,000
Common Stock [Member]
Number of shares issued on conversion					33,465,590	17,000,000	86,433,293	132,654,640
Number of share issued					29,934,782	29,400,000	49,934,782	29,400,000
Fixed Rate Convertible Notes [Member]
Convertible promissory note principal					$ 1,250,000		$ 1,250,000
Convertible promissory notes interest rate					5.00%		5.00%
Debt maturity date							Mar. 15, 2021
Common stock conversion price | $ / shares					$ 0.015		$ 0.015
Description of call feature							The Company has the option to issue a notice of its intent to redeem, for cash, an amount equal to the sum of (a) 120% of the then outstanding principal balance, (b) accrued but unpaid interest and (c) all liquidated damages and other amounts due in respect of the Fixed Rate Convertible Notes. The Company may only issue the notice of its intent to redeem the Fixed Rate Convertible Notes if the trading average of the Company’s common stock equals or exceeds 300% of the conversion price during each of the five business days immediately preceding the date of the notice of intent to redeem.
Convertible notes outstanding					$ 60,301		$ 60,301
Number of converted shares | shares							4,020,092
Fixed Rate Convertible Notes [Member] | Common Stock [Member]
Convertible debt conversion value							$ 17,480
Number of shares issued on conversion							3,495,943
Convertible Notes [Member]
Convertible promissory note principal			$ 265,000	$ 265,000
Debt instrument, monthly payment			$ 1,962
Frequency of periodic payment			Monthly
Convertible promissory notes interest rate			5.95%
Debt maturity date			Jun. 30, 2021
Description of collateral			Secured by the commercial real estate, guarantees by the Company and its real estate subsidiary and the personal guarantee of a stockholder who is also an officer of the Company.
Convertible Notes [Member] | Majority Stockholder [Member]
Number of converted shares | shares									7,450,000
Convertible debt conversion value									$ 29,250
Variable Rate Convertible Notes [Member]
Convertible promissory note principal					$ 41,250		$ 41,250
Variable Rate Convertible Notes [Member] | Minimum [Member]
Convertible promissory notes interest rate					10.00%		10.00%
Variable Rate Convertible Notes [Member] | Maximum [Member]
Convertible promissory notes interest rate					12.00%		12.00%
Variable Rate Convertible Notes [Member] | Third Parties [Member]
Description of maturity							September 2020 and December 2020
Net of financing costs					$ 578,125		$ 578,125
Variable Rate Convertible Notes [Member] | Common Stock [Member]
Number of converted shares | shares							41,250,000
2019 Fixed Rate Convertible Notes [Member]
Frequency of periodic payment							Semi-annually
Convertible promissory notes interest rate					7.00%		7.00%
Common stock conversion price | $ / shares					$ 0.015		$ 0.015
Description of call feature							The Company has the option to issue a notice of its intent to redeem, for cash, an amount equal to the sum of (a) 120% of the then outstanding principal balance, (b) accrued but unpaid interest and (c) all liquidated damages and other amounts due in respect of the Fixed Rate Convertible Notes #2. The Company may only issue the notice of its intent to redeem the Fixed Rate Convertible Notes $2 if the trading average of the Company’s common stock equals or exceeds 300% of the conversion price during each of the five business days immediately preceding the date of the notice of intent to redeem. The holder of the Fixed Rate Convertible Notes #2 has the right to convert all or any portion of the Fixed Rate Convertible Notes #2 at the conversion price at any time prior to redemption.
Convertible notes outstanding					$ 762,000		$ 762,000
Deferred loan costs					739,500		739,500
Convertible Notes [Member]
Convertible promissory note principal					243,125		$ 243,125
Description of maturity							December 31, 2020
Convertible Notes [Member] | Subsequent Event [Member]
Convertible promissory note principal										$ 243,125
5% Convertible Promissory Notes [Member]
Convertible promissory note principal					$ 580,108		$ 580,108		515,247
5% Convertible Promissory Notes [Member] | Common Stock [Member]
Number of shares issued on conversion							116,021,700
Accrued interest									$ 103,132,226

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	Jul. 19, 2019	Nov. 12, 2015	Dec. 31, 2019	Jun. 30, 2019
SERIES A PREFERRED STOCK [Member]
Number of shares issued		215
SERIES B PREFERRED STOCK [Member]
Number of shares issued
Consultant Agreement [Member] | Drew Pinsky, Inc [Member]
Number of shares issued			68,700,000
Percentage of royalty to net sale			3.00%
Agreement terms	The Company’s Sharps Needle and Destruction Device (“SANDD”) mini™, SANDD Pro™ and any related products and/or accessories (“Products”) for an initial period of two (2) years (“Initial Period”), under the terms and conditions described in the Agreement. At the end of the Initial Period, there shall be an automatic, immediately consecutive two (2) year extension period unless DPI, within 60 days of the expiration of the Initial Period, provides written notice of its intention not to extend the Agreement.
Contractual obligation number of share issued			68,700,000
Consultant Agreement [Member] | Drew Pinsky, Inc [Member] | SANDD mini TM [Member]
Royalty be less than unit sold			$ 3.50
Consultant Agreement [Member] | Drew Pinsky, Inc [Member] | SANDD Pro TM [Member]
Royalty be less than unit sold			$ 13.50
Settlement Agreement [Member]
Principal amount			$ 15,000
Settlement agreement terms			(i) Mr. Schreiber and the Schreiber Trust shall transfer all RedHawk stock they presently own (52,377,108 common shares) to RedHawk and (ii) Redhawk shall (a) make to Mr. Schreiber and the Schreiber Trust a cash payment of Two Hundred Fifty Thousand and 00/100 Dollars (US$250,000.00) and (b) issue two Promissory Notes, each in the principal amount of Two Hundred Thousand and 00/100 Dollars (US$200,000.00), one of which shall be due and payable on or before September 6, 2020 and the other shall be due and payable on or before September 5, 2021.
Settlement amount			$ 250,000
Settlement shares			52,377,108
Issue promissory notes			$ 200,000
Promissory note interest rate			18.00%
Settlement loss				$ 471,880
Security Agreement [Member] | SERIES A PREFERRED STOCK [Member]
Number of shares issued			1,473
Security Agreement [Member] | SERIES B PREFERRED STOCK [Member]
Number of shares issued			1,000

STOCKHOLDERS' EQUITY (Details N

STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)	Feb. 16, 2016	Nov. 12, 2015	Jun. 20, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Aug. 20, 2018
Preferred stock, authorized				5,000		5,000		5,000
Common stock, authorized				2,000,000,000		2,000,000,000		2,000,000,000	2,000,000,000
Dividends, preferred stock, paid-in-kind						$ 77,345	$ 77,160
Common Stock issued				1,170,708,112		1,170,708,112		1,034,340,037
Common Stock par value (in dollars per shares)				$ 0.001		$ 0.001		$ 0.001
Warrant outstanding				113,508,450		113,508,450
Exercise price (in dollars per shares)				$ 0.005		$ 0.005
Number of shares issued on conversion				55,916,667
Gain on extinguishment of debt						$ 44,527
SERIES A PREFERRED STOCK [Member]
Number of shares issued on conversion
Series B 5% Convertible Preferred Stock [Member]
Preferred stock, authorized	1,250
Preferred stock, stated value (in dollars per share)	$ 1,000
Preferred stock cumulative dividend rate	5.00%
Description of preferred stock voting rights	Holders of the Series B Preferred Stock are entitled to votes on all matters submitted to stockholders at a rate of ten votes for each share of common stock into which the Series B Preferred Stock may be converted.
Preferred stock, paid-in-kind, per share	$ 0.01
Series A 5% Convertible Preferred Stock [Member]
Preferred stock, authorized		2,750
Preferred stock, stated value (in dollars per share)		$ 1,000
Preferred stock cumulative dividend rate		5.00%
Description of preferred stock voting rights		Holders of the Series A Preferred Stock are entitled to votes on all matters submitted to stockholders at a rate of ten votes for each share of common stock into which the Series A Preferred Stock may be converted.
Preferred stock, paid-in-kind, per share		$ 0.015
Warrant [Member] | 2019 Fixed Rate Convertible Notes [Member]
Common Stock par value (in dollars per shares)				$ 0.01		$ 0.01
Number of warrants issued				19,050,000		19,050,000
Warrant term				10 years		10 years
G. Darcy Klug [Member] | Stock Exchange Agreement [Member]
Common Stock issued			113,700,000
Common Stock par value (in dollars per shares)			$ 0.001
G. Darcy Klug [Member] | Warrant [Member] | Stock Exchange Agreement [Member]
Warrant outstanding			113,508,450
Exercise price (in dollars per shares)			$ 0.005
Warrant expire date			Jun. 20, 2029
Stock Exchange Agreement [Member] | G. Darcy Klug [Member] | SERIES A PREFERRED STOCK [Member]
Preferred stock cumulative dividend rate			5.00%			5.00%
Number of shares converted			1,277
Discription of stock split						0.015 as adjusted for stock splits and dividends.
Stock Exchange Agreement [Member] | G. Darcy Klug [Member] | Warrant [Member]
Common Stock issued				113,508,450		113,508,450
Common Stock par value (in dollars per shares)				$ 0.005		$ 0.005
Warrant expire date				Jun. 30, 2029		Jun. 30, 2029
Common Stock [Member]
Number of shares issued on conversion				33,465,590	17,000,000	86,433,293	132,654,640
5% Convertible Promissory Notes [Member]
Convertible promissory note principal				$ 580,108		$ 580,108		$ 515,247
Conversion price (in dollars per share)				$ 0.005		$ 0.005
5% Convertible Promissory Notes [Member] | Common Stock [Member]
Number of shares issued on conversion						116,021,700
Gain on extinguishment of debt						$ 419,000

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	6 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Net operating losses carryforwards	$ 5,000,000	$ 1,000,000
Description income tax future year	Approximately $4 million of this NOL will expire commencing in fiscal 2026 and run through 2038.
Deferred tax assets operating loss carryforwards		$ 750,000
Reduced percentage of federal tax rate	21.00%
Percentage of deferred tax assets valuation allowance	100.00%

SEGMENT INFORMATION (Details)

SEGMENT INFORMATION (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019
Operating revenues	$ 18,757	$ 48,852	$ 69,315	$ 95,520
Operating income (loss)	(409,180)	(212,814)	(603,865)	(320,828)
Interest expense	123,643	92,615	211,515	181,218
Depreciation and amortization	20,959	30,402	41,917	61,151
Identifiable assets	2,665,642	2,223,545	2,665,642	2,223,545	$ 2,309,333
LAND & HOSPITALITY [Member]
Operating revenues	16,853	14,759	26,603	24,509
Operating income (loss)	(10,501)	3,285	(15,976)	(2,203)
Interest expense	12,891	3,841	26,569	7,737
Depreciation and amortization	7,833	7,834	15,667	15,667
Identifiable assets	919,515	943,966	919,515	943,966
MEDICAL DEVICE & PHARMA [Member]
Operating revenues	1,904	34,093	42,712	71,011
Operating income (loss)	(130,313)	(34,335)	(197,610)	(84,761)
Interest expense	212		317
Depreciation and amortization	13,126	22,568	26,250	45,484
Identifiable assets	201,189	1,117,450	201,189	1,117,450
OTHER SERVICES [Member]
Operating revenues
Operating income (loss)	(75)	(21)	(75)	(201)
Interest expense
Depreciation and amortization
Identifiable assets	77,849		77,849
CORPORATE [Member]
Operating revenues
Operating income (loss)	(268,291)	(181,743)	(390,204)	(233,663)
Interest expense	110,540	88,774	184,629	173,481
Depreciation and amortization
Identifiable assets	$ 1,467,089	$ 162,129	$ 1,467,089	$ 162,129